Ocular Therapeutix (OCUL) Prices 3.725M Share Common Offering at $21.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
December 15, 2020 9:47 PM ESTBEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50 per share for gross proceeds of approximately $80.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional... More
